Sun, Sep 21, 2014, 6:12 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

heman_s 1 post  |  Last Activity: Jul 15, 2014 10:33 PM Member since: Mar 25, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • I am seeing a lot of optimism on twitter regarding the upcoming 012 trial comparing ERT and migalastat in subjects with GLP HEK amenable mutations. The optimism mostly stems from the recently completed 011 study which compared migalastat vs placebo. Due to the limitation of the # of words on twitter I will ask the questions here and quote on twitter. I had a few questions.

    Does anyone know of any published eGFR for patients on ERT ?
    Has amicus disclosed values of any eGFR in migalastat treated patients. All I see is that at 18-24 months eGFR is stable.
    EMA requirement is a non inferiority vs ERT .Is there any other phase 1/2 data to support the view that migalastat is as efficacious as ERT.
    12 and 24 months results from 011 were due in 2H 2013 but were not released untill April 2014, any reason ?

    Dont start correcting for gramr or spelling mistakes.

    If you don't have the answer just #$%$ rather then correcting my english/typing skills.

    Sentiment: Hold

2.80-0.20(-6.67%)Sep 19 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.